Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years.

@article{Deugnier2011ImprovementIL,
  title={Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years.},
  author={Yves Deugnier and Bruno Turlin and Martine Ropert and Maria Domenica Cappellini and John B. Porter and Vanessa Giannone and Yiyun Zhang and Louis H. Griffel and Pierre Brissot},
  journal={Gastroenterology},
  year={2011},
  volume={141 4},
  pages={1202-11, 1211.e1-3}
}
BACKGROUND & AIMS Most data on the effects of iron chelation therapy for patients with liver fibrosis come from small studies. We studied the effects of the oral iron chelator deferasirox on liver fibrosis and necroinflammation in a large population of patients with iron overload β-thalassemia. METHODS We studied data from 219 patients with β-thalassemia, collected from histologic analyses of biopsy samples taken at baseline and after at least 3 years of treatment with deferasirox. Treatment… CONTINUE READING